Subscribe

Receive updates about our latest products in your inbox

Register For Our Next Webinar

Enhancing Longevity: The Synergy of GLP-1 and Mitochondrial Health in Extending Healthspan

About Us

For over 40 years, Biotics Research Corporation has revolutionized the nutritional supplement industry by utilizing “The Best of Science and Nature”. Combining nature’s principles with scientific ingenuity, our products magnify the nutritional

Search the Blog

  • There are no suggestions because the search field is empty.

Ellagic Acid & NAFLD

iStock-1165937163

The results of a randomized, double-blind, placebo-controlled trial investigating the effects of ellagic acid on multiple metabolic markers among people with non-alcoholic fatty liver disease (NAFLD) were recently published in BMC Complementary Medicine and Therapies. This trial enrolled 44 non-obese participants between ages 18 and 55 (mean age ~ 40) diagnosed with NAFLD by hepatic ultrasound, who were then evenly and randomly divided to receive either 180 mg of ellagic acid or a placebo per day. This was an 8-week trial, with markers of glycemic control, lipid profiles, liver enzymes, oxidative stress markers, and inflammatory markers measured at baseline and at the study’s conclusion.  

Ellagic acid supplementation was associated with significant decreases in fasting insulin and the HOMA-IR index, but not fasting glucose levels. Supplementation was also associated with significant reductions in triglycerides and LDL-C, as well as hepatic enzymes (AST, ALT, ALP, GGT) and markers of oxidative stress (malondialdehyde) and inflammation (C-reactive protein). Some of these effects were clinically meaningful, including a mean decrease of -5.82 ng/mL in CRP, and -12.8 mg/dL LDL-C. No significant changes were observed in the group receiving placebo. 

Ellagic acid is a polyphenol found in many fruits, especially pomegranates, persimmons, raspberries and grapes. It has been widely recognized as a potent antioxidant, but has also been investigated for hepatoprotective, anti-lipid, and anti-inflammatory properties, and as an inducer of nuclear factor erythroid 2-related factor2 (Nrf2), which may partly explain its antioxidant effects. Previously published clinical trials suggest it may target components of the metabolic syndrome, highlighting its potential as a therapy for NAFLD. 

Submit your comment

Related Post